Literature DB >> 20371391

Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection.

Florence Faurez1, Daniel Dory, Vincent Le Moigne, Rodolphe Gravier, André Jestin.   

Abstract

DNA vaccination has been widely studied to develop new, alternative, efficient and safe vaccines for humans and animals. Many efforts have been made to increase the immunising potential of these vaccines and three veterinary vaccines are now available on the market. Much work is also being dedicated to develop effective DNA vaccines for humans. However, this new vaccination technique raises issues concerning biosafety due to the nature of the vector, i.e. a DNA molecule that contains sequences of prokaryotic origin (e.g. genes for antibiotic resistance). This review describes the development of the new generation of DNA vectors that are partially or completely devoid of elements of prokaryotic origin and outlines the results of studies on the fate of plasmids after their injection in vivo. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371391     DOI: 10.1016/j.vaccine.2010.03.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Effect of active immunization against a recombinant mouse granulocyte-macrophage colony-stimulating factor/somatostatin fusion protein on the growth of mice.

Authors:  Bingbing Wu; Ruili Qi; Bin Li; Taoyan Yuan; Heshan Liu; Jun He; Zhiwei Lin; Weifen Li; Yan Fu; Dong Niu
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

3.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

4.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

5.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

6.  Vaccines against Toxoplasma gondii: status, challenges and future directions.

Authors:  Qi Liu; Lachhman Das Singla; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

7.  A DNA vaccine against Escherichia coli O157:H7.

Authors:  Kowsar Shariati Mehr; Seyed Latif Mousavi; Iraj Rasooli; Jafar Amani; Masoumeh Rajabi
Journal:  Iran Biomed J       Date:  2012

8.  MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.

Authors:  Wei-Wei Shen; Zhi Zeng; Wen-Xia Zhu; Guo-Hui Fu
Journal:  J Mol Med (Berl)       Date:  2013-04-26       Impact factor: 4.599

9.  Mapping Uncertainties in the Upstream: The Case of PLGA Nanoparticles in Salmon Vaccines.

Authors:  Kåre Nolde Nielsen; Børge Nilsen Fredriksen; Anne Ingeborg Myhr
Journal:  Nanoethics       Date:  2011-03-29       Impact factor: 0.917

10.  Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses.

Authors:  Wynette M Dietz; Nicole E B Skinner; Sara E Hamilton; Michelle D Jund; Suzanne M Heitfeld; Adam J Litterman; Patrick Hwu; Zhi-Ying Chen; Andres M Salazar; John R Ohlfest; Bruce R Blazar; Christopher A Pennell; Mark J Osborn
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.